DOCSLIB.ORG

Biologics & Biosimilars

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biologics & Biosimilars INVENTING WITH PURPOSE CORPORATE RESPONSIBILITY REPORT (2018/2019) COMPLETE WEBSITE COPY AND DATA NOVEMBER 2019 OUR PURPOSE | Overview Our Purpose Overview We have a legacy of saving and improving We live our core commitment to sustainable impact responsibility for using resources wisely and minimizing lives by creating sustainable impact. by managing our business responsibly, following our our environmental footprint. calling to find solutions for some of the world’s most Our approach to corporate responsibility is about the For more than a century, we have been inventing debilitating diseases, striving to reach those in need health, economic, social and environmental impact medicines and vaccines for many of the world’s most with our medicines and vaccines and helping to build we have on individuals and communities around the challenging diseases and we have built a company with robust, durable health systems worldwide through world. We hold ourselves accountable to our many the talent, tenacity and strength to take on some of the partnership, investment and innovation. stakeholders, including patients, employees, customers biggest threats to human and animal health. Operating responsibly as a business is and shareholders, whose perspectives help to define our Reflecting our commitment to managing environmental, corporate responsibility priorities. social and governance (ESG) issues, we continue to at the very heart of our ability to deliver focus our approach to corporate responsibility in four sustainable impact—driving long-term primary areas that are of greatest relevance to our value for our company and society. business and society. y Access to Health We cultivate innovation and excellence by building a diverse and inclusive global workforce, who are y Employees empowered to succeed, personally and professionally. y Environmental Sustainability We anchor ourselves and our partners to the y Ethics & Values highest ethical and business standards, and we take Corporate Responsibility Report 2018/2019 2 OUR PURPOSE | Overview Sustainable Development Goals Philanthropy (SDGs) Through our long history of philanthropy, we continue to demonstrate our commitment to sustainable impact. In addition to responding to the needs of stakeholders, Our philanthropic contributions, product donations and our corporate responsibility efforts also support the 17 employee volunteering efforts, help find solutions to key Sustainable Development Goals (“SDGs”) adopted by global health challenges and strengthen communities the United Nations in 2015 to help end poverty, protect where our employees live and work. the environment and ensure prosperity. Our program investments aim to support interventions We have joined global leaders to that have shown evidence of effectiveness in advancing address the goals on health and the quality of health services delivery, reducing health well-being, clean water, climate care disparities, fostering innovation in the delivery change, diversity and inclusion, of health care, and empowering patients as active responsible consumption and participants in managing their own health. Learn more production and others. about our approach to philanthropy. Our support of the SDGs is a testament to our company’s Total Philanthropy 018 125+ year legacy of inventing for life to create a healthier word for all. For more information, please visit our Sustainable Development Goals page. Sills-Based Volunteering $3.M Product $2.8B Cash Grants Donations Contributions $2.B $84M Corporate Responsibility Report 2018/2019 3 OUR PURPOSE | Letter from Our CEO Letter from Our CEO Environmental Sustainability and Ethics & Values. care systems. Working with more than 160 partners, It represents our commitment to widely recognized our programs have improved access to quality care and reporting frameworks that reflect key environmental, modern contraception for more than nine million women social and governance issues, and our support for in 48 countries. the 10 universally accepted principles of the UN I am proud that our investigational vaccine is being Global Compact. delivered and having an impact in areas of Central Our industry is facing some challenging headwinds, Africa affected by the Ebola virus. Some may say that but our commitment to corporate responsibility will investing to develop an Ebola vaccine doesn’t make good not waiver. The number of health care and drug pricing business sense, but I believe this is the kind of challenge reforms being considered is possibly at an all-time high. that MSD was designed to tackle. Health care costs, especially a patient’s out-of-pocket Corporate responsibility initiatives like MSD for costs, need to be addressed. We want to help find a Mothers and our investigative Ebola vaccine make us an sustainable solution, and we will continue to work with attractive employer for people who want to change the stakeholders and be transparent about our efforts. We world. And it adds to the sense of purpose that keeps have a history of responsible pricing and publicly disclose us going. information about our prices in the United States. This DISCLOSURES IN THIS SECTION includes our pledge not to increase our average net That purpose was captured by our modern-day founder, GRI 102-14 prices across our portfolio by more than the rate of George W. Merck, who said, “Medicine is for the people, inflation annually. not for the profits.” For me, only two metrics truly At MSD, we have been committed to our mission matter—how many people you help, and how much help Whatever may come, we remain steadfast in our focus of saving and improving lives for nearly 130 years. you give those people. on following the science to see where we can have the Over that time, we have been responsible for some greatest impact on patients’ lives. After all, R&D is Promoting enduring social good and securing business of the most significant scientific advancements and the main source of the biopharmaceutical industry’s success are inextricably linked. While there is always improvements in public health. value to society. As we look to the future, we’re more to do, I would like to thank all our employees, our Any one individual can make the scientific breakthrough making investments in our pipeline and manufacturing suppliers and our partners for the work they do every needed to discover a new medicine. I’m reminded of capability to help protect one billion more lives by 2030. day toward these goals. The activities highlighted in this our esteemed former colleague, Maurice Hilleman, report are a testament to the incredible impact they are the father of modern vaccines, whose centenary we Our industry is facing some challenging having all around the world. celebrate this year. However, it takes the infrastructure headwinds, but our commitment to Sincerely, of a company like MSD to translate invention into a corporate responsibility will not waiver. product that can help millions of people every day. Operating responsibly as a business is at the very heart We have a legacy of tackling urgent global health of our ability to do so. challenges. For example, MSD for Mothers, our global Kenneth C. Frazier Our 2018/2019 Corporate Responsibility Report initiative to reduce maternal mortality around the Chairman and Chief Executive Officer reviews our progress against our four key areas of world, empowers women to make informed choices; corporate responsibility: Access to Health, Employees, equips health care providers; and strengthens health Corporate Responsibility Report 2018/2019 4 OUR PURPOSE | Our Business Our Business DISCLOSURES IN THIS SECTION Our businesses include pharmaceuticals, Products GRI 102-2 vaccines and animal health. We are a global health care company that delivers GRI 102-6 We continue to focus our research on conditions that innovative health solutions through our prescription represent some of today’s most significant health medicines, vaccines, biologic therapies and animal health We are inspired by a shared vision and products. View the list of products marketed in the mission to save and improve lives. challenges—like cancer, HIV, HPV, hepatitis C, cardio- metabolic disease, antibiotic-resistant infection and United States. RESOURCES Alzheimer’s disease, and we are on the front lines in the Prescription products fight against emerging global pandemics, such as Ebola. 10-K Product Pipeline Our core business is the discovery and development of We also devote extensive time and energy to increasing prescription medicines for diseases and conditions that access to medicines and vaccines through far-reaching impact millions of people. programs that donate and deliver our products to the Our Corporate Company Fact We invest billions of research dollars to find medicines people who need them. Website Sheet that can help improve lives. Today, our company has We’re applying our global more than 50 prescription products in key therapeutic With a steady focus on innovation and sound science, we reach, financial strength areas such as cardiovascular disease, respiratory work to deliver vaccines, medicines, and animal health and scientific excellence $42.3B disease, oncology, neuroscience, infectious disease, products that can help millions around the world. to doing more of what 2018 revenue immunology and women’s health. we’re passionate about: Our core product categories include diabetes, cancer, improving health and vaccines and hospital acute care. improving lives. Corporate Responsibility Report 2018/2019 5 OUR PURPOSE | Our Business We are a global health care company Senior leadership with a 125-year history of working to Our chairman and CEO, Ken Frazier, is accountable to make a difference. our company’s Board of Directors. Vaccines Learn more about our Board members, including Vaccines are one of the greatest public health success committee charters and assignments. Our Executive stories in history, and our company has played its part in Committee manages the business. These top leaders, that story. representing diverse areas of the company, meet regularly to review progress against our company goals. We have been working to discover and develop vaccines View the list of Executive Committee members.
Load more

Recommended publications
  • European Life Science Ceo Forum
    WELCOME SPONSORS SPEAKERS PRESENTING COMPANIES 3rd Annual EUROPEAN LIFE SCIENCE CEO FORUM for PARTNERING & INVESTING AWARDS ORGANISATIONS PARTNERING 11-12 February 2010 ConventionPoint, Zurich, Switzerland Conference Guide REGIONAL PARTNERS ORGANISERS EUROPEAN LIFE SCIENCE CEO FORUM www.sachsforum.com WELCOME SPONSORS next Welcome Sachs Associates are delighted to welcome you to the: SPEAKERS PRESENTING COMPANIES 3rd Annual European Life Science CEO Forum for Partnering & Investing 11-12 February 2010 ConventionPoint, Zurich, Switzerland Sachs Associates are delighted to welcome you to the 3rd Annual European Life Science CEO Forum for Partnering & Investing. Following its success from previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. This exclusive and transactional event complements our Annual Biotech in Europe Investor Forum, held later in the year, but with added focus on Partnering & the pharmaceutical industry, feature presentations from Big Pharma representatives demonstrating their AWARDS ORGANISATIONS PARTNERING current and future partnering strategies through thought-provoking case studies. This year’s programme features a series of panels and presentations from leading investment, pharmaceutical and biotech companies, highlighting the current issues surrounding the evolving M&A market, Vaccines, Medtech Investment and includes special keynote speeches, providing an expert outlook on Europe’s Biotech industry. In addition, the event holds more than 50 company presentations from an exciting and diverse range of publicly listed and private life science companies, looking to raise fi nance and/or fi nd partners. This year’s DyoDelta Life Science Innovation Awards takes place in the evening of the 11th February and the awards recognise exceptional performance in key categories of partnering and fi nancing within the industry.
    [Show full text]
  • 9780813810461.Pdf
    Nursing Care of the Hospitalized Older Patient Nursing Care of the Hospitalized Older Patient Edited by Terry Mahan Buttaro and Kate A. Barba A John Wiley & Sons, Inc., Publication This edition first published 2013 © 2013 by John Wiley & Sons, Inc Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley’s global Scientific, Technical and Medical business with Blackwell Publishing. Editorial Offices 2121 State Avenue, Ames, Iowa 50014-8300, USA The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 9600 Garsington Road, Oxford, OX4 2DQ, UK For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Publishing, provided that the base fee is paid directly to the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license by CCC, a separate system of payments has been arranged. The fee codes for users of the Transactional Reporting Service are ISBN-13: 978-0-8138-1046-1/2013. Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book.
    [Show full text]
  • Listening, Responding and Working Toward a Healthier Future
    Listening, responding and working toward a healthier future OUR COMMITMENT, PERFORMANCE, IMPACT AND ASPIRATIONS Corporate Responsibility 2006–2007 Report FOLD HINGE SPINE HINGE Our Medicines and Vaccines PRODUCT NAME THERAPEUTIC AREA ATHEROSCLEROSIS & CARDIOVASCULAR Cozaar® (losartan potassium) High blood pressure Hyzaar® (losartan potassium and hydrochlorothiazide) High blood pressure Sustainable business success depends on making quality products that Vytorin® (ezetimibe/simvastatin)* High cholesterol Zetia® (ezetimibe)* High cholesterol DIABETES & OBESITY people value, on sound fi nancial stewardship and on responsible governance Janumet® (sitagliptin/metformin HCI) Type 2 diabetes Januvia® (sitagliptin phosphate) Type 2 diabetes INFECTIOUS DISEASES that ensures we meet customers’ needs ethically and transparently. Atripla® (efavirenz 600mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)† HIV infection Cancidas® (caspofungin acetate) Certain fungal infections Ut wisi enim ad minim veniam, quis Duis autem vel eum iriure dolor in Duis autem vel eum iriure dolor in Ut wisi enim ad minim veniam, quis Duis autem vel eum iriure dolor in Duis autem vel eum iriure dolor in consequat,Crixivan vel® (indinavir illum sulfate) dolore eu feugiat ullamcorper suscipit lobortis nisl utHIV infectionullamcorper suscipit lobortis nisl ut nostrud exerci tation hendrerit in vulputate velit esse molestie hendrerit in vulputate velit esse molestie nostrud exerci tation hendrerit in vulputate velit esse molestie hendrerit in vulputate velit esse molestie nulla Invanzfacilisis.® (ertapenem sodium) aliquip ex ea commodo consequat.Certain bacterialaliquip infections ex ea commodo consequat. consequat, vel illum dolore eu feugiat consequat, vel illum dolore eu feugiat consequat, vel illum dolore eu feugiat consequat, vel illum dolore eu feugiat Isentress® (raltegravir) HIV infection Duis autem vel eum iriure dolor in nulla facilisis.
    [Show full text]
  • Pharmacology for the Health Care Professions
    Pharmacology for the Health Care Professions Christine M. Thorp University of Salford, UK A John Wiley & Sons, Ltd., Publication Pharmacology for the Health Care Professions Pharmacology for the Health Care Professions Christine M. Thorp University of Salford, UK A John Wiley & Sons, Ltd., Publication This edition first published 2008 2008 by John Wiley & Sons, Ltd. Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley’s global Scientific, Technical and Medical business with Blackwell Publishing. Registered office: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Other Editorial Offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher. Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books. Designations used by companies to distinguish their products are often claimed as trademarks.
    [Show full text]
  • Merck 2012 Corporate Respon
    CORPORATE RESPONSIBILITY REPORT 2011 CORPORATE RESPONSIBILITY CORPORATE RESPONSIBILITY At Merck, corporate responsibility is our daily commitment to discovering innovative solutions to the world’s biggest health challenges. It is this simple promise that informs all of our actions as we apply our global resources, our talents and our scientific and operational expertise to some of the most significant health, environmental and economic challenges in the world today. We see corporate responsibility as a major business objective, not solely a philanthropic initiative. Ultimately, it helps us to discover better ways to deliver greater value to both shareholders and society. Through innovative research, groundbreaking partnerships and smarter processes, we are focusing on four priority areas: Access to Health, Environmental Sustainability, Employees, and Ethics & Transparency. With a focus on these priority areas across our entire organization, we are committed to leading the future of healthcare. 2011 MERCK CORPORATE RESPONSIBILITY REPORT 2 CORPORATE RESPONSIBILITY CEO LETTER Merck is leading the way to a healthier future with products of eliminating river blindness, that touch the lives and improve the well-being of people and a leading cause of preventable communities around the world. Our product portfolio is among blindness, and lymphatic filariasis, the broadest in the healthcare industry. As a leader in global more commonly known as healthcare, we are committed to addressing critical social, elephantiasis. Building on this environmental and economic challenges to ensure not only the legacy of tackling urgent global vitality of our business, but also the health of our world. health challenges such as river blindness, HIV/AIDS and hepatitis, That’s why innovation and corporate responsibility are at the core in September we launched “Merck of our business strategy and activities.
    [Show full text]
  • Ambulatory Patient Safety Toolkit
    2011 Ambulatory Patient Safety Toolkit Property of HealthPartners A resource for clinicians and staff provided by HealthPartners Ambulatory Safety Program Introduction HealthPartners is committed to eliminating harm due to error in the delivery of medical care. The HealthPartners Ambulatory Safety Toolkit provides practical tools and suggestions that you may wish to incorporate into clinical operations or adapt to create your own initiatives. We include links to national and local safety resources and protocols, organized by topic. A complete listing of HealthPartners administrative policies can be found on the Provider Portal at healthpartners.com/portal/p178.html. To date, relatively little research has focused on patient safety in the ambulatory setting. Yet most care is delivered in these settings. Although the ambulatory setting might seem less intense (and less “dangerous”) than an inpatient setting, lapses in safety can and do occur, with adverse consequences. A “culture of patient safety” is an essential ingredient of the safe health care organization. “Culture” can be understood as habits, attitudes, and beliefs that live in the minds of the people who work in the organization and guide the work that they do. Concepts closely related to “culture” are “environment” and “mindset.” The knowledge, skill and judgment of the clinician are essential, of course. In the modern group practice, clinic, and outpatient center, the clinician operates through organizational systems and processes, which together produce the desired clinical outcome. Research has shown that serious errors occur more often from a failure of process and systems, rather than the action of a single individual. Well-designed systems and processes allow the organization to deliver care with reliability, consistency, and resiliency (the ability to detect and quickly recover from an error, before harm occurs).
    [Show full text]
  • 2008 Corporate Responsibility Report. on Behalf of the Board, I Am Very Pleased to Note THOMAS E
    Advancing the Dialogue Toward a Healthier Future Corporate Responsibility 2008 Report Criteria from Millennium UN Global Global Reporting the Access to Development Compact TABLE OF CONTENTS Page Initiative Indicators Medicines Index* Goals† Principles About Merck and this report Inside front cover Message from the CEO 1 Message from the Board 2 Merck’s Approach to CR Reporting 3 » Materiality assessment process 3 » Stakeholder engagement 3 Economic Contribution to Society 4 EC1, SO1 MDG 4; MDG 6; MDG 8 Target 8E » Supporting our communities 5 Summary of Our Progress and Future Plans 6 Researching New Medicines and Vaccines to Address Unmet Needs 8 MDG 4 » R&D impact and performance 9 » Current research pipeline 10 » Expanding our research capabilities and results 10 » Intensifying our research capabilities into diseases prevalent 12 C1, C3, C4 in the developing world » Clinical research and disclosure of results 12 PR3 Principle 10 » Future goals and priorities 14 » Fostering science education 14 EC8, EC9 MDG 2 Improving Access to Medicines, Vaccines and Health Care 16 EC8, EC9 H » Access strategy and management 16 A1, (A2), A3 » Key considerations for our activities 17 D1, D2, E2, F1, F2, G1, G2 » Improving access in the developing world and 19 B2, B3, E3 MDG 1; MDG 4 emerging markets » Improving access to vaccines and immunization 22 B3, E3 MDG 4; MDG 8 Target 4 in the developing world » Improving access to HIV/AIDS treatment and care 23 B3 MDG 4; MDG 6; in the developing world MDG 8 Target 4 » Improving access in developed countries
    [Show full text]